GeneInCell

Epigenetic reprogramming is emerging as one of the most intriguing ideas in aging research—the possibility that aging is not just damage, but also a reversible loss of cellular identity. In this episode, we explore how scientists are trying to reset the epigenetic instructions that control gene expression, tissue function, and biological age. We break down the science behind partial reprogramming,...

Aptamers are emerging as powerful “chemical antibodies” that can bind targets with high precision while offering advantages in design, synthesis, and stability. In this episode, we explore how these short nucleic acid ligands are selected, how they work, and why they are gaining attention as next-generation tools for diagnostics, targeted delivery, and therapy. We also discuss their potential to r...

Antisense oligonucleotides are redefining medicine by programming RNA to silence disease at its source. In this episode, we explore how these short, sequence-designed molecules bind target RNA to reduce harmful protein production, reshape splicing, and open new possibilities for precision therapeutics. We cover the history, mechanism, chemistry, and growing clinical relevance of ASOs, along with t...

shRNA is a gene-silencing tool that uses the cell’s own RNA interference machinery to reduce harmful protein production. In this episode, we explore how short hairpin RNAs are designed to target specific mutant genes, how they are delivered into cells, and why they hold promise for treating genetic disease through long-lasting gene knockdown.

Base editing is changing the future of gene editing by allowing scientists to rewrite DNA one letter at a time. In this episode, we explore how base editors work, why they offer a more precise alternative to traditional CRISPR cutting, and how they are being used to correct disease-causing mutations. We also look at their growing potential in research and medicine, along with the challenges that r...

siRNAs are transforming medicine by acting as programmable drugs that selectively silence disease-causing genes. In this episode, we explore how small interfering RNAs work through the RNA interference pathway, why they are so powerful for precision therapeutics, and how they are being developed to treat genetic, metabolic, liver, and rare diseases. We also discuss delivery challenges, clinical pr...

Prime editing is a next-generation gene editing tool designed to precisely rewrite DNA—like a search-and-replace function for the human genome. In this episode, we break down how prime editing works, the chemistry behind it, and why it offers a powerful alternative to traditional CRISPR by making targeted changes without creating double-strand breaks. We also explore its applications in disease co...

NAMs are changing how new drugs are developed. We discuss organoids, tissue chips, and AI-based tools, along with the growing FDA and NIH push toward more human-relevant methods that can improve prediction, reduce reliance on animal models, and help bring safer treatments forward faster.

Can we grow new kidneys from stem cells? In this episode, we explore how scientists are using pluripotent stem cells to create kidney organoids that mimic early kidney development. We discuss how these mini-organs help study kidney disease, test new drugs, and move us closer to future regenerative therapies for kidney failure.

What really happens to your cells under stress, in space, and during space travel? In this episode, we zoom in on the physiological, cellular, and molecular levels to uncover how zero gravity affects them.

What does it take to grow a beating human heart in the lab? This episode explores cardiac organoids—self-organizing heart tissues derived from human stem cells that contract, respond to drugs, and model human heart disease. We unpack how iPSCs are guided into cardiac lineages, how electrical and mechanical cues drive maturation, and why these beating mini-hearts are transforming drug safety testin...

In this episode, we explore the AI revolution in healthcare and what 2026 could look like—from smarter diagnostics and personalized treatments to automation that reshapes clinical workflows. We break down the key innovations, emerging trends, and real-world impact of AI on patients, clinicians, and the healthcare system.

Synthetic biology is turning cells into programmable factories, sensors, and therapies. In this episode, we explore how DNA can be engineered like code to build smarter medicines, sustainable biomaterials, and living devices—and what it will take to move these innovations from the lab to the real world.

How do you give “mini-brains” a bloodstream? This episode explores vascular brain organoids—cerebral organoids engineered with endothelial cells, pericytes, and astrocytes to form BBB-like barriers, improve oxygen/nutrient delivery, and accelerate neuronal maturation. We cover why perfusion matters for MEA activity and drug testing, how microvessels enable neurovascular-coupling studies, and what...

Brain organoids are self-organizing “mini-brains” grown from human stem cells that recapitulate key aspects of early neural development. They fire neural networks on MEAs, model neurodevelopmental and neurodegenerative diseases, and offer human-relevant platforms for drug discovery, circuit mapping, and studying brain evolution—while raising important questions about maturity, reproducibility, and...

Grow a “mini-gut” from stem cells—fast. This episode maps the journey from pluripotent cells to functional intestinal organoids, covering key signals (Activin A, Wnt3a/R-spondin, EGF), culture formats (3D domes vs. monolayers), and core readouts (TEER, permeability, metabolism). We highlight use cases in disease modeling and drug testing.

Discover how 3D intestinal organoids—mini-gut tissues grown from stem cells—are transforming preclinical drug testing. We break down how these models capture human barrier function, absorption, metabolism, and host–microbiome interactions better than animal systems, enabling smarter toxicity profiling and efficacy screening. From patient-derived organoids for precision medicine to organoid-on-chip...

DNA as code, cells as computers. We explore how binary models of genomes reveal mutational logic, why evolution mirrors open-source development, and how this lens powers DNA data storage, biomolecular logic gates, and smarter synthetic biology.

Silicon is hitting its limits—and our data keeps exploding. In this episode, we explore DNA as a radical new archive: a medium with hyper-dense capacity and millennia-scale stability that doesn’t need power to preserve information. We unpack the workflow—encoding 1s and 0s into A, T, C, and G; writing short DNA oligos; and reading them back with sequencing plus robust error-correction.

Explore the shift from standard Cas9 nuclease—which makes double-strand breaks—to precision tools like Cas9 nickases (single-strand “nicks”) and dead Cas9 (binding without cutting). We break down how these variants reduce off-target indels and enable safer editing and gene regulation (CRISPRi/a, base/prime editor scaffolds) for high-fidelity genome engineering.

From stem cells to therapies, this episode dives into the world of human liver organoids—how iPSCs are guided into functional “mini-livers,” the bioengineering tricks that mature them, and the breakthroughs they enable in disease modeling, drug screening, and precision hepatology. In this short episode, we unpack what’s real, what’s next, and how organoids are accelerating the path to regenerative...

How PiggyBac moves DNA in—and out—without scars. We cover transposase mechanics (TTAA-site integration and footprint-free excision), large cargo delivery (tens to ~100 kb), and why it’s popular for iPSCs, stable cell lines, and cell therapies.

A quick tour of next-gen models that add functional vascularization and immune cells to boost physiological relevance. And strategies (self-assembly, pre-patterning) to build perfusable microvascular networks for real maturation. Educational only; not medical advice.

How lab-grown mini-retinas model human vision. In this episode, we show how iPSC-derived retinal organoids form layered photoreceptors, enable gene-editing tests (CRISPR, ASOs), and accelerate drug screening for inherited retinal diseases. Clear takeaways, visuals, and translational notes for bench and clinic. Educational only; not medical advice.

How FOXP3-defined Tregs prevent autoimmunity and shape therapy. We trace the discoveries by Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi , unpack Treg biology and assays, and explore translational angles—from autoimmune disease and transplantation to cancer immunotherapy and engineered Tregs. Educational content only; not medical advice.